Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance.

2013

Background: Reversibility of advanced fibrosis after HCV-clearance is an important goal of therapy. Objectives: Measuring liver stiffness (LS) by transient elastography (TE) might be helpful in this setting. Patients and Methods: We evaluated 104 patients with biopsy-proven chronic hepatitis C (CHC) and sustained virological response (SVR) after Peg-Interferon (IFN) plus ribavirin since at least 18 months. HCV-eradication was confirmed searching for serum HCV-RNA (TMA® sensitivity > 5-10 IU/ml). Data from literature reported the best LS cut-off values for different stages of liver fibrosis were 7.1 kPa for Metavir stage 2 (F2), 9.5 kPa for F3 and 12.5 for cirrhosis (F4). Results: TE was not…

Liver Cirrhosismedicine.medical_specialtyPathologyCirrhosisGastroenterologychemistry.chemical_compoundFibrosisInternal medicineBiopsyMedicineStage (cooking)Hepatologymedicine.diagnostic_testbusiness.industryRibavirinmedicine.diseaseKowsarliver stiffnessInfectious DiseaseschemistryElasticity Imaging TechniquesSteatosisInsulin ResistancebusinessTransient elastographyResearch ArticleHepatitis monthly
researchProduct

Fibrosis in chronic viral hepatitis

2011

In the last years, several studies have been performed with the aim to evaluate the real impact of antiviral treatments on fibrosis progression in patients with chronic viral hepatitis. The main goal of therapy in patients with chronic hepatitis B is viral suppression. This outcome leads to an important improvement in both hepatic inflammation and fibrosis and reduces the HCC occurrence. An histological improvement has been largely demonstrated in patient treated with oral nucleoside and nucleotide analogs achieving the rate of 72% with entecavir and tenofovir. Similarly, in patients with chronic hepatitis C, sustained virologic response to interferon therapy is associated with regression o…

Liver Cirrhosismedicine.medical_specialtyPathologyInterferon therapyGastroenterologyHepatitis B ChronicFibrosisInternal medicinemedicineHumansIn patientViral suppressionLiver decompensationliver fibrosisbusiness.industryGastroenterologyEntecavirHepatitis C Chronicmedicine.diseaseAnti-Retroviral AgentsVirologic responseReverse Transcriptase InhibitorsInterferonsbusinessViral hepatitismedicine.drug
researchProduct

Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice

2006

Background/Aims In hepatic fibrogenesis, stellate cells are activated leading to production and deposition of extracellular matrix. To clarify the role of PDGF-B in liver fibrogenesis, we overexpressed PDGF-B in the liver of transgenic mice. Methods Transgenic mice for the conditional overexpression of PDGF-B in the liver under control of an albumin promoter were generated utilising the Cre/loxP system. Constitutive PDGF-B expression was achieved after breeding with mice expressing Cre-recombinase under actin promoter control. Tamoxifen inducible expression was achieved after breeding with mice expressing Cre under transthyretin receptor promoter control. Levels of fibrosis were assessed an…

Liver Cirrhosismedicine.medical_specialtyPlatelet-derived growth factorLiver cytologyTransgeneMice TransgenicBiologyMicechemistry.chemical_compoundTransforming Growth Factor betaFibrosisInternal medicinemedicineAnimalsPromoter Regions GeneticCells CulturedCell ProliferationIntegrasesHepatologyTransdifferentiationCell DifferentiationProto-Oncogene Proteins c-sisFibroblastsmedicine.diseaseExtracellular MatrixEndocrinologyGene Expression RegulationLiverchemistryHepatocytesCancer researchHepatic stellate cellHepatic fibrosisMyofibroblastJournal of Hepatology
researchProduct

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-…

2020

The impact of direct-acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA-based treatment. Patients (260) were enrolled in the German Hepatitis C-Registry (DHC-R), a national multicentre real-world cohort. Liver stiffness (LS) was assessed at baseline, end of treatment (EOT) and 24 weeks after EOT (FU24) by TE. Biochemical, virological and clinical data were obtained in parallel. In patients with SVR, there was a significant improvement of LS between baseline (median [range], 8.6 [1.7-73.5] kPa) and FU24 (7.9 […

Liver Cirrhosismedicine.medical_specialtySustained Virologic ResponseBilirubinMedizinGastroenterologyAntiviral AgentsVirusTransaminase03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrosisVirologyInternal medicineGermanymedicineHumans030212 general & internal medicineRegistriesHepatitisHepatologybusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryLiverCohortElasticity Imaging Techniques030211 gastroenterology & hepatologybusinessTransient elastographyJournal of viral hepatitisREFERENCES
researchProduct

Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets

2014

Background & Aims Nonalcoholic fatty liver disease is a common consequence of human and rodent obesity. Disruptions in lipid metabolism lead to accumulation of triglycerides and fatty acids, which can promote inflammation and fibrosis and lead to nonalcoholic steatohepatitis. Circulating levels of fibroblast growth factor (FGF)21 increase in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis; therefore, we assessed the role of FGF21 in the progression of murine fatty liver disease, independent of obesity, caused by methionine and choline deficiency. Methods C57BL/6 wild-type and FGF21-knockout (FGF21-KO) mice were placed on methionine- and choline-deficient (MCD)…

Liver Cirrhosismedicine.medical_specialtyTime FactorsBiologyInfusions SubcutaneousSeverity of Illness IndexArticleHepatitischemistry.chemical_compoundAcyl-CoAMethionineNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsRNA MessengerMice Knockoutchemistry.chemical_classificationHepatologyFatty acid metabolismFatty AcidsFatty liverGastroenterologyFatty acidmedicine.diseaseRecombinant ProteinsCholine DeficiencyFibroblast Growth FactorsMice Inbred C57BLDisease Models AnimalEndocrinologyLiverchemistryLipotoxicityDisease ProgressionLipid PeroxidationInflammation MediatorsSteatosisLong chain fatty acidOxidation-ReductionGastroenterology
researchProduct

Early Steroid-Free Immunosuppression With FK506 After Liver Transplantation: Long-Term Results of a Prospectively Randomized Double-Blinded Trial

2010

Background. The aim of this prospective, randomized, double-blinded, placebo-controlled single center study was to evaluate an early steroid-free immunosuppression in liver transplant patients. Methods. From March 2000 to October 2004, 110 patients were included. All patients received tacrolimus and steroids during the first 2 weeks after orthotopic liver transplantation (OLT). Thereafter, patients in the steroid group (n=54) received steroids and the remaining 56 a placebo. After 6 months, the immunosuppression for all was steroid free. Thirty patients were hepatitis C positive. Five years after inclusion, patient survival, organ survival, steroid side effects, and recirrhosis in hepatitis…

Liver Cirrhosismedicine.medical_specialtyTime Factorsmedicine.medical_treatmentHypercholesterolemiaLiver transplantationSingle CenterPlaceboGastroenterologyTacrolimusPostoperative ComplicationsDouble-Blind MethodAdrenal Cortex HormonesRecurrenceInternal medicineDiabetes MellitusmedicineHumansSurvival rateAntibacterial agentTransplantationDose-Response Relationship Drugbusiness.industryGraft SurvivalImmunosuppressionHepatitis Cmedicine.diseaseHepatitis CTacrolimusLiver TransplantationSurgerySurvival RateTreatment OutcomebusinessImmunosuppressive AgentsTransplantation
researchProduct

Liver stiffness in chronic hepatitis C virus infection

2019

Abstract Introduction . The severity of liver fibrosis can be assessed noninvasively today by liver stiffness measurements. Vibration-controlled transient elastography, shear wave elastography or magnetic resonance elastography are techniques increasingly used for this purpose. Methods . This article presents the recent advances in the use of new techniques for liver fibrosis assessment in chronic hepatitis C: the correlation between liver stiffness values and liver fibrosis estimated by liver biopsies, the prognosis role of liver stiffness values, their usefulness in monitoring the treatment response, in assessing the severity of portal hypertension and in estimating the presence of esopha…

Liver Cirrhosismedicine.medical_specialtymacromolecular substancesGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineEsophageal varicesInternal medicinemedicineHumansInternal medicineliver fibrosisshear wave elastographybusiness.industryStiffnessHepatitis CHepatitis C Chronicmedicine.diseaseequipment and suppliestransient elastographyRC31-1245RheumatologyMagnetic resonance elastographyliver stiffnessLiver030220 oncology & carcinogenesisPortal hypertensionchronic hepatitis c030211 gastroenterology & hepatologymedicine.symptombusinessTransient elastographyRomanian Journal of Internal Medicine
researchProduct

NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease

2021

Background and Aims: Farnesoid X receptor (FXR) plays a key role in bile acid and lipid homeostasis. Experimental evidence suggests that it can modulate liver damage related to nonalcoholic fatty liver disease (NAFLD). We examined the impact of the NR1H4 rs35724 G>C, encoding for FXR, on liver damage in a large cohort of patients at risk of steatohepatitis. Methods: We considered 2,660 consecutive individuals at risk of steatohepatitis with liver histology. The rs35724 G>C polymorphisms were genotyped by TaqMan assays. Gene expression was evaluated by RNASeq in a subset of patients (n = 124). Results: The NR1H4 rs35724 CC genotype, after adjusting for clinic-metabolic and genetic conf…

Liver Cirrhosismedicine.medical_specialtymedicine.drug_classReceptors Cytoplasmic and NuclearGastroenterologyBile Acids and Saltschemistry.chemical_compoundNon-alcoholic Fatty Liver DiseaseFibrosisSettore BIO/13 - Biologia ApplicataInternal medicineNAFLDNonalcoholic fatty liver diseasemedicineHumansReceptor Fibroblast Growth Factor Type 4Settore MED/12 - GastroenterologiaHepatologyBile acidCholesterolbusiness.industryNASHObeticholic acidmedicine.diseaseNR1H4LiverchemistryFXRSteroid HydroxylasesFarnesoid X receptorSteatohepatitisSteatosisbusiness
researchProduct

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.

2010

AbstractChelation therapy with new drugs prevents cardiac damage and improves the survival of thalassemia patients. Liver diseases have emerged as a critical clinical issue. Chronic liver diseases play an important role in the prognosis of thalassemia patients because of the high frequency of viral infections and important role of the liver in regulating iron metabolism. Accurate assessment of liver iron overload is required to tailor iron chelation therapy. The diagnosis of hepatitis B virus– or hepatitis C virus–related chronic hepatitis is required to detect patients who have a high risk of developing liver complications and who may benefit by antiviral therapy. Moreover, clinical manage…

Liver Cirrhosisthalassemiamedicine.medical_specialtyCirrhosisC VIRUS-INFECTION; HOMOZYGOUS BETA-THALASSEMIA; TRANSFUSION-DEPENDENT THALASSEMIA; TERM-FOLLOW-UP; IRON OVERLOAD; LIVER-DISEASE; INTERFERON-ALPHA; RISK-FACTORS; INTRAFAMILIAL TRANSMISSION; HEPATOCELLULAR-CARCINOMAHepatitis C virusThalassemiaImmunologymedicine.disease_causeChronic liver diseaseAntiviral AgentsBiochemistryHOMOZYGOUS BETA-THALASSEMIALiver diseaseHepatitis B ChronicLIVER-DISEASEHEPATOCELLULAR-CARCINOMAmedicineTRANSFUSION-DEPENDENT THALASSEMIAIRON OVERLOADHumansIntensive care medicineTERM-FOLLOW-UPchronic viral hepatitis; thalassemia; managementbusiness.industryCell BiologyHematologyHepatitis CHepatitis C ChronicHepatitis Bmedicine.diseaseINTRAFAMILIAL TRANSMISSIONchronic viral hepatitisImmunologyRISK-FACTORSINTERFERON-ALPHAViral hepatitisbusinessC VIRUS-INFECTIONmanagement
researchProduct

Diagnostica non invasiva delle varici esofagee nei pazienti con cirrosi epatica: dati ecografici vs dati endoscopici

2008

The aim of this study was to identify possible clinical, biochemical or instrumental markers which can predict in a non-invasive manner the presence of EV. One hundred and fifty-eight consecutive liver cirrhotic patients seen at our outpatient clinic were included in this study. The diagnosis of LC was done on liver biopsy findings or based on instru m e n t a l , clinical and serological data. Patients underwent EGE, ultra - sound of the upper abdomen, Doppler of the main splancnic vessels and the main parameters of liver function were tested. Liver cirrhosis was mostly correlated to hepatitis C virus and most patients were class A according to Child. At EGE, EV w e re absent in 41 patient…

Liver cirrhosis esophageal varices ultrasound esophago-gastro-duodenoscopy portal hypertension
researchProduct